Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Inflammatix
AddedFeb 15, 2024
UpdatedJun 18, 2026
Inflammatix

Inflammatix

Seed

Inflammatix, Inc.: A novel diagnostics company founded in 2016, offering management consulting services.

HQ
Burlingame, CA, US
Founded
2016
Overview
Compare
Fundraising
Employees
Website

Inflammatix, Inc. is a novel diagnostics company founded in 2016, focused on developing advanced diagnostic tests that interpret the immune response to inform on key clinically actionable questions. Their products are designed to assist emergency medicine physicians in evaluating hard-to-diagnose patients. Although still in development and not yet approved for sale by regulatory authorities, their innovative approach aims to revolutionize patient care by providing precise and timely diagnostic information.

Since its inception, Inflammatix has made significant strides in the field of medical diagnostics. The company's pioneering TriVerity test, which is currently under development, exemplifies their commitment to enhancing diagnostic accuracy and improving patient outcomes. By leveraging cutting-edge technology to analyze the immune response, Inflammatix is poised to make a substantial impact on the healthcare industry once their products receive regulatory approval.

Inflammatix - Similar Companies

InflammX Therapeutics logo

InflammX Therapeutics

inflammx.com

Empowered Diagnostics logo

Empowered Diagnostics

Predictive Health Diagnostics Company logo

Predictive Health Diagnostics Company

Amplified Sciences logo

Amplified Sciences

Veramarx logo

Veramarx

veramarx.com

Evanostics logo

Evanostics

Inflammatory Response Research logo

Inflammatory Response Research

irrinc.net

Inmedix logo

Inmedix

inmedix.com

Intellimedix logo

Intellimedix

Inflammasome Therapeutics logo

Inflammasome Therapeutics

inflam.com

Instadiagnostics logo

Instadiagnostics

Celestia Diagnostics logo

Celestia Diagnostics

Akili Labs logo

Akili Labs

ImmunoProfile logo

ImmunoProfile

immunoprofile.com

Inception IBD logo

Inception IBD

Inflammatix - Quick Facts

Who are Inflammatix's competitors?

Companies similar to Inflammatix include InflammX Therapeutics, Empowered Diagnostics, Predictive Health Diagnostics Company and Amplified Sciences.

When was Inflammatix founded?

Inflammatix was founded in 2016.

Where is Inflammatix's headquarters located?

Inflammatix's headquarters is located in Burlingame, CA, US.

When was Inflammatix's last funding round?

Inflammatix's most recent funding round was for $1.7M (USD) in November 2021.

How much has Inflammatix raised to-date?

As of Nov 11, 2021, Inflammatix has raised a total of $137.8M (USD).

How many employees does Inflammatix have?

Inflammatix has 75 employees as of Feb 5, 2024.

Inflammatix - Classification

Ownership
  • Venture Capital
Technology
  • Analytics
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Diagnostic Tests
Tags
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software